Cargando…

Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial

IMPORTANCE: Reducing myopia progression can reduce the risk of associated ocular pathologies. OBJECTIVE: To evaluate whether spectacle lenses with higher lenslet asphericity have a higher myopia control efficacy throughout 2 years. DESIGN, SETTING, AND PARTICIPANTS: This double-masked randomized cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Jinhua, Huang, Yingying, Li, Xue, Yang, Adeline, Zhou, Fengchao, Wu, Junqian, Wang, Chu, Li, Yuhao, Lim, Ee Woon, Spiegel, Daniel P., Drobe, Björn, Chen, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972151/
https://www.ncbi.nlm.nih.gov/pubmed/35357402
http://dx.doi.org/10.1001/jamaophthalmol.2022.0401
_version_ 1784679781582766080
author Bao, Jinhua
Huang, Yingying
Li, Xue
Yang, Adeline
Zhou, Fengchao
Wu, Junqian
Wang, Chu
Li, Yuhao
Lim, Ee Woon
Spiegel, Daniel P.
Drobe, Björn
Chen, Hao
author_facet Bao, Jinhua
Huang, Yingying
Li, Xue
Yang, Adeline
Zhou, Fengchao
Wu, Junqian
Wang, Chu
Li, Yuhao
Lim, Ee Woon
Spiegel, Daniel P.
Drobe, Björn
Chen, Hao
author_sort Bao, Jinhua
collection PubMed
description IMPORTANCE: Reducing myopia progression can reduce the risk of associated ocular pathologies. OBJECTIVE: To evaluate whether spectacle lenses with higher lenslet asphericity have a higher myopia control efficacy throughout 2 years. DESIGN, SETTING, AND PARTICIPANTS: This double-masked randomized clinical trial was conducted between July 2018 and October 2020 at the Eye Hospital of Wenzhou Medical University in Wenzhou, China. Children aged 8 to 13 years with a cycloplegic spherical equivalent refraction (SER) of −0.75 D to −4.75 D and astigmatism with less than −1.50 D were recruited. A data and safety monitoring committee reviewed findings from a planned interim analysis in 2019. INTERVENTIONS: Participants were randomly assigned in a 1:1:1 ratio to receive spectacle lenses with highly aspherical lenslets (HAL), spectacle lenses with slightly aspherical lenslets (SAL), or single-vision spectacle lenses (SVL). MAIN OUTCOME AND MEASURES: Two-year changes in SER and axial length and their differences between groups. RESULTS: Of 157 participants who completed each visit (mean [SD] age, 10.4 [1.2] years), 54 were analyzed in the HAL group, 53 in the SAL group, and 50 in the SVL group. Mean (SE) 2-year myopia progression in the SVL group was 1.46 (0.09) D. Compared with SVL, the mean (SE) change in SER was less for HAL (by 0.80 [0.11] D) and SAL (by 0.42 [0.11] D; P ≤ .001). The mean (SE) increase in axial length was 0.69 (0.04) mm for SVL. Compared with SVL, increase in axial length was slowed by a mean (SE) of 0.35 (0.05) mm for HAL and 0.18 (0.05) mm for SAL (P ≤ .001). Compared with SVL, for children who wore HAL at least 12 hours every day, the mean (SE) change in SER was slowed by 0.99 (0.12) D, and increase in axial length slowed by 0.41 (0.05) mm. CONCLUSIONS AND RELEVANCE: In this study, HAL and SAL reduced the rate of myopia progression and axial elongation throughout 2 years, with higher efficacy for HAL. Longer wearing hours resulted in better myopia control efficacy for HAL. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR1800017683
format Online
Article
Text
id pubmed-8972151
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-89721512022-04-20 Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial Bao, Jinhua Huang, Yingying Li, Xue Yang, Adeline Zhou, Fengchao Wu, Junqian Wang, Chu Li, Yuhao Lim, Ee Woon Spiegel, Daniel P. Drobe, Björn Chen, Hao JAMA Ophthalmol Original Investigation IMPORTANCE: Reducing myopia progression can reduce the risk of associated ocular pathologies. OBJECTIVE: To evaluate whether spectacle lenses with higher lenslet asphericity have a higher myopia control efficacy throughout 2 years. DESIGN, SETTING, AND PARTICIPANTS: This double-masked randomized clinical trial was conducted between July 2018 and October 2020 at the Eye Hospital of Wenzhou Medical University in Wenzhou, China. Children aged 8 to 13 years with a cycloplegic spherical equivalent refraction (SER) of −0.75 D to −4.75 D and astigmatism with less than −1.50 D were recruited. A data and safety monitoring committee reviewed findings from a planned interim analysis in 2019. INTERVENTIONS: Participants were randomly assigned in a 1:1:1 ratio to receive spectacle lenses with highly aspherical lenslets (HAL), spectacle lenses with slightly aspherical lenslets (SAL), or single-vision spectacle lenses (SVL). MAIN OUTCOME AND MEASURES: Two-year changes in SER and axial length and their differences between groups. RESULTS: Of 157 participants who completed each visit (mean [SD] age, 10.4 [1.2] years), 54 were analyzed in the HAL group, 53 in the SAL group, and 50 in the SVL group. Mean (SE) 2-year myopia progression in the SVL group was 1.46 (0.09) D. Compared with SVL, the mean (SE) change in SER was less for HAL (by 0.80 [0.11] D) and SAL (by 0.42 [0.11] D; P ≤ .001). The mean (SE) increase in axial length was 0.69 (0.04) mm for SVL. Compared with SVL, increase in axial length was slowed by a mean (SE) of 0.35 (0.05) mm for HAL and 0.18 (0.05) mm for SAL (P ≤ .001). Compared with SVL, for children who wore HAL at least 12 hours every day, the mean (SE) change in SER was slowed by 0.99 (0.12) D, and increase in axial length slowed by 0.41 (0.05) mm. CONCLUSIONS AND RELEVANCE: In this study, HAL and SAL reduced the rate of myopia progression and axial elongation throughout 2 years, with higher efficacy for HAL. Longer wearing hours resulted in better myopia control efficacy for HAL. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR1800017683 American Medical Association 2022-03-31 2022-05 /pmc/articles/PMC8972151/ /pubmed/35357402 http://dx.doi.org/10.1001/jamaophthalmol.2022.0401 Text en Copyright 2022 Bao J et al. JAMA Ophthalmology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Bao, Jinhua
Huang, Yingying
Li, Xue
Yang, Adeline
Zhou, Fengchao
Wu, Junqian
Wang, Chu
Li, Yuhao
Lim, Ee Woon
Spiegel, Daniel P.
Drobe, Björn
Chen, Hao
Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial
title Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial
title_full Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial
title_fullStr Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial
title_full_unstemmed Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial
title_short Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial
title_sort spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972151/
https://www.ncbi.nlm.nih.gov/pubmed/35357402
http://dx.doi.org/10.1001/jamaophthalmol.2022.0401
work_keys_str_mv AT baojinhua spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT huangyingying spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT lixue spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT yangadeline spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT zhoufengchao spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT wujunqian spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT wangchu spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT liyuhao spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT limeewoon spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT spiegeldanielp spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT drobebjorn spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial
AT chenhao spectaclelenseswithasphericallensletsformyopiacontrolvssinglevisionspectaclelensesarandomizedclinicaltrial